Racura Oncology Ltd
RAC
Company Profile
Business description
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,185.90 | 70.20 | 0.77% |
| CAC 40 | 8,430.79 | 16.48 | -0.20% |
| DAX 40 | 24,934.67 | 24.26 | 0.10% |
| Dow JONES (US) | 51,492.55 | 507.12 | -0.98% |
| FTSE 100 | 10,508.61 | 14.40 | 0.14% |
| HKSE | 24,312.16 | 181.79 | -0.74% |
| NASDAQ | 26,021.66 | 354.69 | -1.34% |
| Nikkei 225 | 69,902.25 | 497.75 | 0.72% |
| NZX 50 Index | 13,346.86 | 46.12 | -0.34% |
| S&P 500 | 7,420.10 | 91.25 | -1.21% |
| S&P/ASX 200 | 8,966.30 | 65.50 | 0.74% |
| SSE Composite Index | 4,108.08 | 16.18 | 0.40% |